Introduction {#Sec1}
============

Deep vein thrombosis (DVT) occurred in 3.5% of intensive care unit (ICU) patients and 1.3% in hospitalized patient in medicine wards \[[@CR1], [@CR2]\].

A hallmark of patients affected by coronavirus disease 2019 (COVID-19) is coagulopathy.

Mechanism and pathogenesis is still not clear, although excessive inflammation, hypoxia, immobilization and diffuse intravascular coagulation could be possible factors associated with high incidence of thromboembolism \[[@CR3], [@CR4]\].

Clinical observations stemming from patients admitted to intensive care units (ICU) showed that several patients have signs of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE) \[[@CR5], [@CR6]\]*.*

The purpose of this study was to explore the incidence of DVT in COVID-19 patients and correlate it with the severity of the disease as well as with clinical and laboratory findings.

Materials and methods {#Sec2}
=====================

A total number of 234 patients, with the mean age of 61.63 years, including 164 females (70%) and 70 males (30%), diagnosed with coronavirus disease 2019 admitted in our Hospital from March 15th and April 7th 2020 were included in our study (Table [1](#Tab1){ref-type="table"}).Table 1Variables list and descriptive statisticsContinuous variables*N*MinMaxMeanstandard devAge (years)23479861.6314.21BMI (kg /m^2^)5623.1542.929.085.14Time from symptoms onset (days)2280367.214.63Admission to DUS time (days)23303410.148.29Systolic blood pressure (mmHg)23390180130.0317.43Diastolic blood pressure (mmHg)2334510073.5711.06Heart rate (beats per minute)2344013080.1915.05FiO~2~1650.310.490.14SpO~2~2310.9510095.556.97PF ratio19557472225.4597.51Respiratory rate (breaths per minute)232124021.694.88Platelet (cells/mm3)23345812328.28145.40INR2290.0444.31.180.33Partial thromboplastin time2311.0177.934.017.49D-dimer (µg/mL)229200906814006.08900.1Fibrinogen (mg/dl)2091201139509.14190.62IL-6 (pg/mL)681.554359.0990.95Ferritin (ng/mL)22869.4150331278.381627.82C reactive protein (mg/L)232034.155.746.50Procalcitonin (ng/mL)1530.0240.80.613.37Heparin dosage (UI)2022850125005653.221799.23Categorical variables*N*%Sex Male7029.90 Female16470.10Smoke Yes20386.75 No2611.11COPD Yes187.69 No21190.17Asthma Yes104.27 No21993.59Fever Yes20788.46 No2510.68Cough Yes14160.26 No8938.03Dyspnea Yes15666.67 No7632.48Chest pain Yes62.56 No22495.73Other symptoms Yes10042.74 No13457.26Asthenia Yes2912.39 No20587.61Myalgia100.00 Yes125.13 No22294.87Gastroenteric symptoms Yes3213.68 No20286.32Alteration of consciousness Yes166.84 No21893.16Upper airways symptoms Yes104.27 No22495.73Deep vein thrombosis risk factors Yes4217.95 No19282.05Cancer Yes2611.11 No20888.89Cardiovascular risk factors Yes13858.97 No9641.03Obesity Yes3715.81 No19784.19Hypertension Yes9339.74 No14160.26Ischemic heart disease Yes177.26 No21792.74Myocardial infarction Yes83.42 No22696.58Diabetes Yes4017.09 No19482.91Dyslipidemia Yes239.83 No21190.17Prolonged bed rest Yes15264.96 No8235.04Venous catheter Yes156.41 No21993.59Ward type High intensity of care4619.66 Mid-intensity of care12854.70 Low intensity of care6025.64O~2~ therapy Nasal cannula2912.39 Venturi/reservoir4217.95 C-PAP8536.32 Orotracheal intubation7833.33Heparin administration q24 h10143.16 q12 h12553.42 q8 h83.42

All the patients were diagnosed according to the World Health Organization (WHO) guidelines \[[@CR7]\]. These patients underwent a series of investigations, including clinical examinations, laboratory tests, chest X-ray (CXR), sometimes computed tomography (CT), and real-time reverse transcriptase polymerase chain reaction (rRT-PCR) for SARS-CoV-2. The severity of the disease of the hospitalized patients was judged according to the Seventh Revised Edition of the "The diagnosis and treatment plan for the novel coronavirus disease" \[[@CR8]\] in moderate, severe and critical disease, and patients were sorted in Low intensity care units (LICU), Mid-intensive Care Units (MICU) and Intensive Care Units (ICU), respectively.

All patients were asymptomatic and were underwent to Doppler ultrasound (DUS) examination. Two skilled operators performed the bedside examinations, with portable US machines available in each ward and using the linear probe (Fig. [1](#Fig1){ref-type="fig"}). DUS findings were classified as positive or negative; femoral and/or popliteal thrombosis was considered as positive DVT (Figs. [2](#Fig2){ref-type="fig"}a, b, [3](#Fig3){ref-type="fig"}a, b, c).Fig. 1Thrombosis of the common femoral veinFig. 2A, B: Partial thrombosis of the popliteal veinFig. 3**a**, **b**, **c** Floating thrombus of the common femoral vein

All the continuous and categorical variables analyzed are summarized in Table [1](#Tab1){ref-type="table"} and include clinical, laboratory's and therapeutic factors. Each patient needed oxygen (O~2~) therapy and was treated at least with prophylactic heparin administration (Table [1](#Tab1){ref-type="table"}).

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. No informed consent was required.

The study was approved by our Institutional Review Board (Radcovid03/2020).

SPSS v25.0 (IBM, Chicago, IL) was used for all statistical analyses; *p*values were considered significant when \< 0.05.

A correlation between the DUS result (positive/negative) and many clinical, laboratory's and therapeutic variables (see Table [1](#Tab1){ref-type="table"} for variables list) was investigated by contingency tables and Pearson chi square test for categorical variables and by Student *t* test and Fisher\'s exact test for continuous variables. Continuous variables that showed a significant correlation were studied also with ROC curve analysis.

Results {#Sec3}
=======

The 234 patients included in the study were hospitalized as follows: 46 in ICU, 128 in MICU and 60 in LICU (Table [1](#Tab1){ref-type="table"}).

At DUS, asymptomatic DVT finding was reported in 25/234 cases (10.7%). Contingency tables and Pearson chi square test showed a good association for prolonged bedrest and ward type. Only 2 out of 82 were self-mobilizing versus 23 out of 152 bedrest patients showed DVT on DUS (sensitivity: 92.0%; specificity: 38.3%; *p*value: 0.003). Moreover, only 1 out of 60 low-intensity care wards patients (1.6%) versus 15 out of 128 mid-intensity care wards (11.7%) and 9 out of 46 high-intensity care wards patients (19.6%) showed DVT on DUS (chi square 9.05; *p* value: 0.01).

Student *t* test and Fisher\'s exact test showed good associations for ventilation, therapeutic and laboratory's variables. More in detail, deep vein thrombosis was found in patients with an higher fraction of inspired oxygen (*p* value: 0.002), a lower P/F ratio (*p* value: 0.0007) and an higher respiratory rate (*p* value: 0.049); moreover, in these patients heparin dosage was higher, despite number of administration per day (q24 h / q12 h / q8 h). Higher values of d-dimer (*p* value: 0.000004) and IL-6 levels (*p* value: 0.002), higher ferritin (*p* value: 0.01), and higher C reactive protein (*p* value: 0.004) were found in patients with DVT compared with those without DVT. Moreover, time between hospital admission and DUS was lower in DVT patients (*p* value: 0.03). Details are shown in Table [2](#Tab2){ref-type="table"} and Fig. [4](#Fig4){ref-type="fig"}. ROC curve (Table [3](#Tab3){ref-type="table"} and Fig. [5](#Fig5){ref-type="fig"}) showed the highest AUC for IL-6 (0.820) with a sensitivity of 83.3% and a specificity of 80.6% for a cutoff of 64.95 pg/mL, with an accuracy (AUC) of 82.0%.Table 2Student *t* test results*T* test*p*valueMean ± SD\
DVTMean ± SD\
DVT negativeAge \> 0.0565 ± 10.2861.22 ± 14.57BMI \> 0.0527.23 ± 5.2429.59 ± 5.05Time from symptoms onset \> 0.057.92 ± 4.627.12 ± 4.63Admission to DUS time**0.029**6.6 ± 8.1310.56 ± 8.22Systolic blood pressure \> 0.05130.64 ± 15.9129.96 ± 17.64Diastolic blood pressure \> 0.0570.84 ± 11.2873.9 ± 11.02Heart rate \> 0.0580.36 ± 17.8580.17 ± 14.73FiO~2~**0.0019**0.58 ± 0.20.48 ± 0.13SpO~2~ \> 0.0594.71 ± 2.8795.64 ± 7.3PF ratio**0.00072**168.54 ± 77.4233.44 ± 97.56Respiratory rate**0.049**23.48 ± 4.621.48 ± 4.88Platelet \> 0.05288.8 ± 180.97333.03 ± 140.31INR \> 0.051.2 ± 0.241.18 ± 0.34Partial thromboplastin time \> 0.0534 ± 6.3434.01 ± 7.63D-dimer*0.000004*11571.92 ± 20404.553078.75 ± 5641.83Fibrinogen \> 0.05527.88 ± 250.82506.59 ± 181.64IL-6**0.0021**165.48 ± 121.7648.79 ± 81.55Ferritin**0.010**2080.04 ± 2988.361184.07 ± 1366.14C reactive protein**0.0042**9.23 ± 8.425.32 ± 6.12Procalcitonin \> 0.050.43 ± 0.410.63 ± 3.56Heparin dosage**0.035**6433.33 ± 2256.845562.71 ± 1723.29*SD* Standard Deviation;*BMI* Body Mass Index;*FiO*~2~ Fraction of inspired oxygen;*SPO*~2~ peripheral capillary oxygen saturation;*PF ratio* PaO~2~/FiO~2~ ratio;*INR* international normalized ratioFig. 4Boxplot for significant continuous variablesTable 3ROC curve analysis for significant continuous variables at student *t* testVariableAUCCutoffSensitivitySpecificityAdmission to DUS time (days)0.6619.50.7600.490Heparin dosage (UI)0.61153500.6190.470FiO~2~0.6380.5250.4780.768PF ratio0.701292.50.9170.292Respiratory rate (breaths per minute)0.637190.8800.314D-dimer (µg/mL)0.70721280.6800.706IL-6 (pg/mL)0.82064.950.8330.806Ferritin (ng/mL)0.663907.50.7080.515C reactive protein (mg/L)0.6594.10.7200.570Fig. 5ROC curve for significant continuous variables with AUC \> 0.7

Discussion {#Sec4}
==========

Apart from respiratory failure, coagulopathy is a common abnormality in patients with COVID-19.

Klok FA et al. \[[@CR3]\] reported a high incidence of thrombotic complications (acute pulmonary embolism (PE), deep vein thrombosis, ischemic stroke, myocardial infarction or systemic arterial embolism) in patients with COVID-19 infections (31%) admitted at ICU. All patients received at least standard doses thromboprophylaxis.

Data about the incidence of DVT is scarce. A recent published study has shown an incidence of 25% of DVT in ICU COVID-19 patients; the significant increase of D-dimer resulted as a good index for identifying high-risk patients \[[@CR5]\].

Llitjos JF et al. reported 69% incidence rate of DVT in severe mechanically ventilated COVID-19 patients; all patients were treated with therapeutic anticoagulation from admission \[[@CR6]\].

Even in our Hospital, from the beginning of the outbreak, an unusually high mortality rate due to pulmonary embolism occurred among hospitalized COVID-19 patients who were under prophylactic dose of low molecular weight heparin. Therefore, we decided to implement a screening program for DVT in COVID-19 patients hospitalized.

We found that DVT even occurs in patients treated with therapeutic anticoagulation from admission, highlighting the high thromboembolic potential of COVID19. Bedrest and ICU admission resulted significantly associated with the presence of DVT.

Our results have shown an incidence for DVT of 10.7%, lower than in other mentioned publications. The reason is to be found in the fact that our study is the only one in which even patients less severely affected from low intensity wards were included. In medicine wards we found only 1 out of 60 hospitalized patients, with an incidence of 1.6%, similar to that reported in the same wards in non-COVID-19 patients (1.3%) \[[@CR1], [@CR9], [@CR10]\]. This observation led us to suppose that in less severely affected patients in low-intensity Covid-19 wards, execution of DUS as screening of DVT might be unnecessary. Our overall incidence of DVT increases to 13.8% considering mid-and high-intensity Covid-19 units (24/174).

Strengths of the present study is represented by the large analyzed series, which to date, is the largest in literature. Moreover, an association with clinical, laboratory's and therapeutic parameters was investigated and confirmed for the first time. Indeed, both the fraction of inspired oxygen, P/F ratio and the respiratory rate and heparin administration, d-dimer, IL-6, ferritin and CRP resulted correlated with the presence of DVT.

However, the study presents some limitations, especially in its retrospective design. Moreover, DUS was performed earlier in DVT patients and DVT patients had an higher dose of heparin, so an underestimation of DVT may be suspected in some cases. This suggests that clinical and laboratory suspicion before investigation is always mandatory.

The high rate of DVT found in our severe COVID-19 patients who were under prophylactic treatment and correlation with respiratory parameters and some significant laboratory findings suggests that these can be used as a screening tool for patients who should be getting DUS \[[@CR11]\]. In these patients, DUS may be considered a useful and valid tool for early identification of DVT.
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